• Explore /
  • Poster
  • / Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial versus an external control arm from the Flatiron Health database.

Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial versus an external control arm from the Flatiron Health database.

Abstract Video & Slides Poster

Authors

Robert Coleman

Robert L. Coleman

Texas Oncology, US Oncology Research, The Woodlands, TX

Robert L. Coleman , Qin Shen , Scott Goulden , Cara Amanda Mathews , Matthias Hunger , Ankit Pahwa , Rene Schade

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5593)

DOI

10.1200/JCO.2022.40.16_suppl.5593

Abstract #

5593

Poster Bd #

469

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Quality Care Symposium

Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.

First Author: Jinan Liu

First Author: Florence Joly

First Author: Emily Meichun Ko

First Author: Angela Jain